Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 631 to 645 of 1423 results for primary care

  1. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.

  2. Supporting inter-generational need

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Families and relationships settings...

  3. What is the clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism?

    clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism? Any explanatory notes(if...

  4. Dupilumab for treating moderate to severe atopic dermatitis (TA534)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.

  5. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

    Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.

  6. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  7. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  8. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (HTG677)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.

  9. Stakeholder registration - confidentiality agreement

    This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information

  10. Stakeholder registration - confidentiality agreement

    This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information

  11. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

  12. User guide for the cost comparison company evidence submission template (PMG32)

    This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented

  13. What is the effectiveness and safety of sacral nerve stimulation and transanal irrigation compared to symptomatic treatment for people with major low anterior resection syndrome?

    discharge from hospital, it is important that it can be identified in primary care. LARS should be assessed using a validated tool, for...

  14. Extended access to GP services:- Is extended access to GP services, for example during early mornings, evenings and weekends, more clinically and cost effective than standard access?

    explanatory notes(if applicable) Why this is important:- Continuity of care improves patient experience, aids clinical decision-making...

  15. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.